CPI

Report: Child Care Industry Struggling in Pandemic's Aftermath

Retrieved on: 
Tuesday, January 30, 2024

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Nearly one in five children in families using paid child care services stopped doing so during the pandemic, severely disrupting the child care industry.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Nearly one in five children in families using paid child care services stopped doing so during the pandemic, severely disrupting the child care industry.
  • While the drop in paid child care usage corresponds with a decline in the number of children of child care age, the report reveals that many other traditional economic, demographic, and child care market factors known to influence the use of paid child care do not adequately explain the industry's weak recovery.
  • Traditional economic, demographic, and child care market factors do not explain the extent of the decline in paid child care usage.
  • Other factors such as work-from-home, shifts in parental preferences, and a reduced supply of paid child care are plausible contributors to the weak rebound in the use of paid care.

EQS-News: CPI PROPERTY GROUP – Muddy Waters Part 2

Retrieved on: 
Tuesday, January 30, 2024

CPI PROPERTY GROUP (“CPIPG”) acknowledges the publication of a second report by Muddy Waters.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG”) acknowledges the publication of a second report by Muddy Waters.
  • Similar to the first report, the second attempt includes sensational statements, recycled criticisms and poor research.
  • The first report by Muddy Waters had no impact on CPIPG’s access to liquidity, disposals, or other strategic plans.
  • CPIPG is confident that our disclosures are accurate, and we are proud to be fully transparent and open.

EQS-News: CPI PROPERTY GROUP – Muddy Waters Part 3

Retrieved on: 
Tuesday, January 30, 2024

CPI PROPERTY GROUP (“CPIPG”) acknowledges the publication of yet another report by Muddy Waters.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG”) acknowledges the publication of yet another report by Muddy Waters.
  • Once again, Muddy Waters used flimsy analysis and damaging terminology to infer wrongdoing and support their short position.
  • Once again, CPIPG will demonstrate that Muddy Waters is wrong.
  • Our comprehensive reply to Parts 2 and 3 of Muddy Waters “research” will be issued as soon as possible; CPIPG will subsequently invite our stakeholders to a webcast with Q&A.

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

Retrieved on: 
Thursday, January 18, 2024

OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.

Key Points: 
  • OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.
  • The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need, including gastric, lung and ovarian cancer.
  • We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients.
  • Trial arms are investigating OBT076 both as a monotherapy and in combination with a CPI in these tumors.

CPI Card Group Names John Lowe President and Chief Executive Officer

Retrieved on: 
Thursday, January 25, 2024

CPI Card Group Inc. (Nasdaq: PMTS) (“CPI” or the “Company”), a payment technology company and leading provider of credit, debit and prepaid solutions, today announced John Lowe has been named its new President and Chief Executive Officer and appointed to the Company’s Board of Directors, effective immediately.

Key Points: 
  • CPI Card Group Inc. (Nasdaq: PMTS) (“CPI” or the “Company”), a payment technology company and leading provider of credit, debit and prepaid solutions, today announced John Lowe has been named its new President and Chief Executive Officer and appointed to the Company’s Board of Directors, effective immediately.
  • Lowe succeeds outgoing President and Chief Executive Officer Scott Scheirman, who had previously announced his intention to retire in early 2024.
  • Lowe has been with CPI Card Group since 2018, most recently as Executive Vice President, End-to-End Payment Solutions since late 2022.
  • He previously served as the Company’s Senior Vice President and General Manager, Secure Card, beginning in 2021, and was the Company’s Chief Financial Officer from 2018 through 2021.

Macroeconomic Researcher Wins Blue Chip Forecasting Award

Retrieved on: 
Wednesday, January 17, 2024

TEMPE, Ariz., Jan. 17, 2024 /PRNewswire/ -- As economic analysts continue to debate the prospects for a soft landing versus a hard fall for the U.S. economy, Michael Cosgrove, principal and founder of The Econoclast®, Inc., predicts a mild recession with more disinflation and at least 100 basis points decline in the funds rate.

Key Points: 
  • At the event, Cosgrove will be honored with the Lawrence R. Klein Award for Blue Chip Forecast Accuracy for 2023, one of the best-known and longest-standing achievements in economic forecasting.
  • A livestream of the forecast and award ceremony will also be available, and is free for the public to view.
  • The winner is selected based on the accuracy of forecasts published in the Blue Chip Economic Indicators newsletter, compiled and edited by Haver Analytics, Inc.
    "I have participated in Blue Chip Economic Indicators for several decades and it is an honor to receive this prestigious award," says Cosgrove.
  • Cosgrove has been a long-term participant in Blue Chip Economic Indicators, The Wall Street Journal survey, Western Blue Chip Economic Indicators, and Pulsenomics, and had best home price forecast at Pulsenomics in 2014.

CPI Aerostructures Appoints Ross Johnson to Leadership Team as Vice President, Program Management

Retrieved on: 
Tuesday, January 16, 2024

EDGEWOOD, N.Y., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) today announced that it has appointed Ross Johnson to the position of Vice President, Program Management.

Key Points: 
  • EDGEWOOD, N.Y., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) today announced that it has appointed Ross Johnson to the position of Vice President, Program Management.
  • Mr. Johnson, 63, has extensive experience in program management, business development, marketing & sales, contracts, engineering technical support, customer support and aircraft operations.
  • Most recently, he served as Director, Program Management at Sikorsky Aircraft, Inc. responsible for aircraft deliveries, customer management, contract execution and leadership of the aircraft build integrated product teams.
  • “The appointment of Ross Johnson aligns with our objectives of achieving industry-leading operations while augmenting CPI Aero's experienced aerospace leadership team.

Direct Source Connects Retailers with Innovative Technology at NRF: Retail’s Big Show 2024

Retrieved on: 
Monday, January 15, 2024

Direct Source , the leading retail technology consultant and integrator, has unveiled the latest in retail technology and will be showcasing solutions at NRF: Retail’s Big Show in New York City January 14-16, booth #5839.

Key Points: 
  • Direct Source , the leading retail technology consultant and integrator, has unveiled the latest in retail technology and will be showcasing solutions at NRF: Retail’s Big Show in New York City January 14-16, booth #5839.
  • "We're thrilled to engage with retailers at NRF 2024,” said Brad Fick, president of Direct Source.
  • Leveraging their comprehensive product knowledge, Direct Source’s technology experts analyze each retailer’s business goals, future technology needs and pain points to create the optimal in-store experience.
  • For more information about Direct Source’s complete retail solutions, visit: www.directsource.com or visit booth #5839 at NRF: Retail’s Big Show.

UNCF Receives $100 Million Grant from Lilly Endowment Inc. to Support Capital Campaign

Retrieved on: 
Thursday, January 11, 2024

“Lilly Endowment’s unrestricted grant will be used as UNCF’s initial investment toward the establishment of an HBCU pooled endowment fund of $370 million,” Lomax said.

Key Points: 
  • “Lilly Endowment’s unrestricted grant will be used as UNCF’s initial investment toward the establishment of an HBCU pooled endowment fund of $370 million,” Lomax said.
  • Through its capital campaign, UNCF will raise $185 million, or $5 million per institution.
  • We are incredibly grateful for Lilly Endowment’s continued support of UNCF and higher education,” said Marc Barnes, senior vice president, capital campaign, UNCF.
  • Our campuses stand ready to work with UNCF to accomplish the $370 million goal for the pooled unrestricted endowment.”

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

Retrieved on: 
Tuesday, January 9, 2024

“We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.

Key Points: 
  • “We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.
  • “Having established an appropriate dose for monotherapy as well as demonstrating its early clinical validation we believe MDNA11 may further enhance anti-tumor activity when combined with pembrolizumab in patients that do not respond or develop resistance to checkpoint therapy.
  • We look forward to reporting preliminary results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.”
    In the Phase 1 monotherapy dose escalation and dose evaluation portions of the study, MDNA11 was well tolerated with promising single-agent activity.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.